BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Akeso readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Akeso's drugs run\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06341335-1994@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT06341335)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: A Study of AK104/Placebo Plus AK
 109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenoca
 rcinoma\nEstimated primary completion: November 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06341335
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06984718-1994@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06984718)
DESCRIPTION:Cadonilimab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pha
 se II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Sec
 ond-line HCC\nEstimated primary completion: 30 November 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06984718
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05689853-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT05689853)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: Study of AK119 Combined With A
 K112 in Patients With Advanced Solid Tumors\nEstimated primary completion:
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivone
 scimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05689853
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943820-2087@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AK129: Phase 1/2 readout est. (NCT06943820)
DESCRIPTION:AK129\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: AK129 C
 ombination Therapy for Advanced Solid Tumors\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ak12
 9#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 943820
URL:https://assetmemo.bio/drug/ak129#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767527-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06767527)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: AK112 or Placebo Plus Nab-Paclit
 axel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Tr
 iple-negative Breast Cancer\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06767527
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07436221-1281@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:AK139: Phase 2 readout est. (NCT07436221)
DESCRIPTION:AK139\, phase 2\, Asthma.\nStudy: A Study to Evaluate the Effic
 acy and Safety of AK139 in Participants With Asthma\nEstimated primary com
 pletion: 27 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ak139#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07436221
URL:https://assetmemo.bio/drug/ak139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646055-1994@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Cadonilimab: Phase 1/2 readout est. (NCT06646055)
DESCRIPTION:Cadonilimab\, phase 1/2.\nStudy: AK112 and Cadonilimab Combined
  With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer\nEstim
 ated primary completion: 30 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06646055
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05227664-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT05227664)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Study of AK117/AK112 in Metast
 atic Triple-Negative Breast Cancer\nEstimated primary completion: 30 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT052
 27664
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05229497-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT05229497)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: A Phase Ib/II Study of AK112 i
 n Combination With AK117 in Advanced Malignant Tumors\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05229497
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06601335-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06601335)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: A Phase 3 Study of AK112 Plus AK
 117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous
  Cell Carcinoma (R/M HNSCC)\nEstimated primary completion: January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06601335
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951503-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06951503)
DESCRIPTION:Ivonescimab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: A
 K112 and Chemotherapy in First-line Metastatic Colorectal Cancer\nEstimate
 d primary completion: 13 January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06951503
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357220-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07357220)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: A Study of AK112 in Combinatio
 n With VG2025 in Colorectal Cancer With Liver Metastases\nEstimated primar
 y completion: 28 February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07357220
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05142423-1994@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Cadonilimab: Phase 1/2 readout est. (NCT05142423)
DESCRIPTION:Cadonilimab\, phase 1/2.\nStudy: A Study of AK109 Combined With
  AK104 in Patients With Advanced Solid Tumors\nEstimated primary completio
 n: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cadoni
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05142423
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07755371-1281@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:AK139: Phase 2 readout est. (NCT07755371)
DESCRIPTION:AK139\, phase 2.\nStudy: A Study to Evaluate the Efficacy and S
 afety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Poly
 ps\nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ak139#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07755371
URL:https://assetmemo.bio/drug/ak139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06938321-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT06938321)
DESCRIPTION:Ivonescimab\, phase 1/2\, Biliary Tract Cancer.\nStudy: A Study
  of AK130 in Combination With AK112 for the Treatment of Advanced Biliary 
 Tract Cancer\nEstimated primary completion: May 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06938321
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06928389-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06928389)
DESCRIPTION:Ivonescimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ivo
 nescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Can
 cer\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06928389
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052253-1994@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07052253)
DESCRIPTION:Cadonilimab\, phase 2\, Hepatocellular Carcinoma.\nStudy: A Pha
 se II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet fo
 r Advanced HCC.\nEstimated primary completion: 10 May 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07052253
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953999-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270514
DTEND;VALUE=DATE:20270515
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06953999)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: A Phase III Study of Ivonescimab
  + Chemo With/Without AK117 in Metastatic Pancreatic Cancer\nEstimated pri
 mary completion: 14 May 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06953999
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767540-1280@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270710
DTEND;VALUE=DATE:20270711
SUMMARY:Manfidokimab: Phase 3 readout est. (NCT06767540)
DESCRIPTION:Manfidokimab\, phase 3\, Atopic Dermatitis.\nStudy: A Clinical 
 Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis\nE
 stimated primary completion: 10 July 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/manfidokimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06767540
URL:https://assetmemo.bio/drug/manfidokimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07883213-1281@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:AK139: Phase 2 readout est. (NCT07883213)
DESCRIPTION:AK139\, phase 2\, Prurigo Nodularis.\nStudy: A Study to Evaluat
 e the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.\nEs
 timated primary completion: August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ak139#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07883213
URL:https://assetmemo.bio/drug/ak139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07114315-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07114315)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Study of AK130 in Combination 
 With AK112 for the Treatment of Advanced Pancreatic Cancer\nEstimated prim
 ary completion: August 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07114315
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669779-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07669779)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small C
 ell Lung Cancer\nEstimated primary completion: 30 August 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07669779
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07591090-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07591090)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Phase II Study of AK146D1 Comb
 ined With AK112 in Advanced Breast Cancer\nEstimated primary completion: 1
  September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivon
 escimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07591090
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686030-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06686030)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: Combination Therapy of AK112 Wit
 h Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer\nEstim
 ated primary completion: October 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06686030
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06642792-2087@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:AK129: Phase 1/2 readout est. (NCT06642792)
DESCRIPTION:AK129\, phase 1/2.\nStudy: A Study of AK129 With or Without AK1
 17 in PD(L)1-refractory Classic Hodgkin Lymphoma\nEstimated primary comple
 tion: November 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ak129#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06642792
URL:https://assetmemo.bio/drug/ak129#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502222-1281@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:AK139: Phase 2 readout est. (NCT07502222)
DESCRIPTION:AK139\, phase 2\, Atopic Dermatitis.\nStudy: A Study to Evaluat
 e the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Ato
 pic Dermatitis\nEstimated primary completion: November 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ak139#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07502222
URL:https://assetmemo.bio/drug/ak139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07449780-1994@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271117
DTEND;VALUE=DATE:20271118
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT07449780)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: A Study of AK104 (SC) in Combina
 tion With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combin
 ation With XELOX in Participants With Unresectable Locally Advanced or Met
 astatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
 \nEstimated primary completion: 17 November 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07449780
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245446-1994@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07245446)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: A Study of Ivonescimab in First-
 Line ES-SCLC\nEstimated primary completion: December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07245446
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767514-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06767514)
DESCRIPTION:Ivonescimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Cli
 nical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Pa
 tients With High PD-L1\nEstimated primary completion: April 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06767514
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07228832-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT07228832)
DESCRIPTION:Ivonescimab\, phase 3\, Metastatic Colorectal Cancer.\nStudy: P
 hase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patie
 nts With Metastatic Colorectal Cancer\nEstimated primary completion: 31 Ma
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07228
 832
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560124-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07560124)
DESCRIPTION:Ivonescimab\, phase 1/2.\nStudy: A Study of AK138D1 Alone or in
  Combination With Ivonescimab in Advanced Breast Cancer\nEstimated primary
  completion: 6 June 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07560124
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623356-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280618
DTEND;VALUE=DATE:20280619
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07623356)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non
 -Small Cell Lung Cancer\nEstimated primary completion: 18 June 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07623356
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636772-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280824
DTEND;VALUE=DATE:20280825
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07636772)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Phase II Study of AK146D1 Mono
  or Combined With AK112 in Advanced Urothelial Carcinoma\nEstimated primar
 y completion: 24 August 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07636772
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158840-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07158840)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: AK1
 12 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actiona
 ble Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase 
 Inhibitor (TKI) Treatment\nEstimated primary completion: September 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07158840
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05899608-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT05899608)
DESCRIPTION:Ivonescimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Cli
 nical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Pa
 tients\nEstimated primary completion: 31 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05899608
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010263-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT07010263)
DESCRIPTION:Ivonescimab\, phase 3.\nStudy: A Study of AK112 as Consolidatio
 n Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Hav
 e Not Progressed Following Concurrent Chemoradiation Therapy\nEstimated pr
 imary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07010263
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07875426-1281@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:AK139: Phase 2 readout est. (NCT07875426)
DESCRIPTION:AK139\, phase 2\, Chronic Spontaneous Urticaria.\nStudy: A Tria
 l to Evaluate the Efficacy and Safety of AK139 in Participants With Chroni
 c Spontaneous Urticaria\nEstimated primary completion: 8 January 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ak139#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07875426
URL:https://assetmemo.bio/drug/ak139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877194-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20290412
DTEND;VALUE=DATE:20290413
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07877194)
DESCRIPTION:Ivonescimab\, phase 2.\nStudy: A Clinical Study of Ivonescimab 
 in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer\nE
 stimated primary completion: 12 April 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07877194
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023315-1994@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT07023315)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: A Phase III Clinical Study of Ca
 donilimab Plus SOX as Perioperative Treatment for Patients With Resectable
  G/GEJ Adenocarcinoma\nEstimated primary completion: July 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07023315
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700979-1994@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20290818
DTEND;VALUE=DATE:20290819
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT07700979)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: Phase 3 Study of Cadonilimab Com
 bined With Chemotherapy vs Chemotherapy in Combination With or Without Niv
 olumab for the 1L Treatment of Participants With HER2-negative\, Previousl
 y Untreated\, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma\nEstim
 ated primary completion: 18 August 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07700979
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07263919-1994@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT07263919)
DESCRIPTION:Cadonilimab\, phase 2.\nStudy: Perioperative Cadonilimab Combin
 ed With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Ca
 rcinoma (ESCC)\nEstimated primary completion: March 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07263919
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412613-1994@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20300615
DTEND;VALUE=DATE:20300616
SUMMARY:Cadonilimab: Phase 3 readout est. (NCT07412613)
DESCRIPTION:Cadonilimab\, phase 3.\nStudy: Neoadjuvant/Adjuvant AK104 in Mi
 crosatellite Instability-high or Mismatch Repair-deficient\, Resectable Co
 lon Cancer\nEstimated primary completion: 15 June 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07412613
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07815665-2023@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Ivonescimab: Phase 2/3 readout est. (NCT07815665)
DESCRIPTION:Ivonescimab\, phase 2/3.\nStudy: A Study of Ivonescimab in Comb
 ination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfor
 tumab Vedotin in Metastatic Urothelial Carcinoma\nEstimated primary comple
 tion: 31 October 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07815665
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
